– GERMANY, Bonn – NEUWAY Pharma GmbH, a highly innovative biotechnology company, today announced the appointment of Dr. Oliver Ernst as CEO, replacing Dr. Heiko Manninga who remains in his current role as CSO and Managing Director.
Dr. Ernst, who joined NEUWAY in 2019 as COO and Managing Director, will now lead the company as CEO.
“It is a privilege to lead NEUWAY at this exciting time as we are rapidly generating highly promising data, advancing our EnPC development program, and entering into new partnerships,” said Dr. Oliver Ernst.
About NEUWAY Pharma
NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules, which can cross the blood-brain barrier and deliver transformative neuro-pharmaceuticals for the treatment of disorders of the central nervous system.
For more information: https://www.neuway-pharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.